Alto Neuroscience 10-Q Filing: Q3 2024 Update
Ticker: ANRO · Form: 10-Q · Filed: 2024-11-12T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotech, clinical-stage, financials
TL;DR
**Alto Neuroscience Q3 10-Q: Financials and clinical updates released. Stay tuned for pipeline progress.**
AI Summary
Alto Neuroscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its clinical-stage assets. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with a crucial update on Alto Neuroscience's financial health and operational progress, particularly concerning its drug development pipeline.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Alto Neuroscience faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- 2024-09-30 — Reporting Period End Date (The end date for the financial and operational data presented in the 10-Q.)
- 2024-11-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241112 (date) — Filing date
- 650 CASTRO STREET, SUITE 450 (address) — Company's business and mailing address
- MOUNTAIN VIEW, CA (location) — Company's city and state
FAQ
What were Alto Neuroscience's total assets as of September 30, 2024?
The filing indicates financial data for the period ending September 30, 2024, but specific total asset figures are not directly extractable from the provided header information.
What is Alto Neuroscience's primary business focus?
Alto Neuroscience is focused on pharmaceutical preparations, as indicated by its Standard Industrial Classification code [2834].
In which state was Alto Neuroscience incorporated?
Alto Neuroscience, Inc. was incorporated in Delaware (DE).
What is the fiscal year end for Alto Neuroscience?
The company's fiscal year ends on December 31 (1231).
What is the SEC file number for Alto Neuroscience?
The SEC file number for Alto Neuroscience is 001-41944.
From the Filing
0001999480-24-000042.txt : 20241112 0001999480-24-000042.hdr.sgml : 20241112 20241112162440 ACCESSION NUMBER: 0001999480-24-000042 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 241448679 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 10-Q 1 alto-20240930.htm 10-Q alto-20240930 12-31 0001999480 2024 Q3 False 0.4462 1.5 xbrli:shares iso4217:USD iso4217:USD xbrli:shares alto:subsidiary alto:clinical-stageAsset utr:Rate alto:tranche alto:loan xbrli:pure alto:invention alto:patentFamily utr:sqft alto:renewal alto:termination 0001999480 2024-01-01 2024-09-30 0001999480 2024-11-08 0001999480 2024-09-30 0001999480 2023-12-31 0001999480 2024-07-01 2024-09-30 0001999480 2023-07-01 2023-09-30 0001999480 2023-01-01 2023-09-30 0001999480 2023-09-30 0001999480 2022-12-31 0001999480 us-gaap:CommonStockMember 2022-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001999480 us-gaap:RetainedEarningsMember 2022-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001999480 alto:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001999480 2023-01-01 2023-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001999480 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001999480 2023-03-31 0001999480 us-gaap:CommonStockMember 2023-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001999480 us-gaap:RetainedEarningsMember 2023-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001999480 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001999480 2023-04-01 2023-06-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001999480 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001999480 2023-06-30 0001999480 us-gaap:CommonStockMember 2023-06-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001999480 us-gaap:RetainedEarningsMember 2023-06-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001999480 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001999480 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001999480 us-gaap:CommonStockMember 2023-09-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001999480 us-gaap:RetainedEarningsMember 2023-09-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001999480 us-gaap:CommonStockMember 2023-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001999480 us-gaap:RetainedEarningsMember 2023-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001999480 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001999480 2024-01-01 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001999480 alto:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001999480 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-03-31 0001999